Osaic Holdings Inc. Has $5.50 Million Holdings in Astera Labs, Inc. $ALAB

Osaic Holdings Inc. grew its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 208.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,787 shares of the company’s stock after acquiring an additional 41,051 shares during the quarter. Osaic Holdings Inc.’s holdings in Astera Labs were worth $5,496,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Oliver Lagore Vanvalin Investment Group acquired a new position in Astera Labs during the 2nd quarter valued at $29,000. Bernard Wealth Management Corp. acquired a new position in shares of Astera Labs during the second quarter valued at about $36,000. Clearstead Trust LLC raised its position in shares of Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after buying an additional 461 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after buying an additional 194 shares during the period. Finally, Manchester Capital Management LLC grew its position in Astera Labs by 141.5% during the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after buying an additional 283 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Price Performance

Shares of NASDAQ:ALAB opened at $172.62 on Tuesday. The business’s fifty day moving average price is $159.19 and its two-hundred day moving average price is $156.48. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The stock has a market capitalization of $29.16 billion, a price-to-earnings ratio of 155.51, a price-to-earnings-growth ratio of 3.06 and a beta of 1.52.

Astera Labs (NASDAQ:ALAB) last issued its earnings results on Tuesday, November 4th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.39 by $0.10. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company had revenue of $230.58 million for the quarter, compared to the consensus estimate of $206.42 million. During the same quarter in the previous year, the company earned $0.23 EPS. The firm’s revenue for the quarter was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Research analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on ALAB. Needham & Company LLC upped their price target on Astera Labs from $205.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. BNP Paribas began coverage on Astera Labs in a research note on Thursday, November 20th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. upped their target price on Astera Labs from $180.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Northland Securities raised their target price on Astera Labs from $175.00 to $195.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, Roth Capital boosted their price target on shares of Astera Labs from $200.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $188.17.

Insider Transactions at Astera Labs

In other Astera Labs news, CFO Michael Truett Tate sold 11,430 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $1,653,806.70. Following the sale, the chief financial officer directly owned 192,297 shares of the company’s stock, valued at approximately $27,823,452.93. This represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Manuel Alba sold 150,000 shares of Astera Labs stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the completion of the transaction, the director owned 1,574,498 shares of the company’s stock, valued at $261,650,077.64. This trade represents a 8.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 586,936 shares of company stock valued at $89,331,140. 12.50% of the stock is owned by company insiders.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.